Erratum: Correction of Reference Citations in Romosozumab Cardiovascular Safety Study

Overview

This erratum addresses errors in the in-text reference citations in the discussion section of the original article comparing cardiovascular safety of romosozumab and PTH analogues. Specifically, references 46-51 were incorrectly cited and have been removed as they were not listed in the reference list.

Background

The original study by Stokar and Szalat evaluated the comparative cardiovascular safety of romosozumab versus PTH analogues in osteoporosis management using propensity-score matching. The discussion included a statement about the lack of an established pathophysiologic mechanism linking romosozumab to cardiovascular effects. However, the in-text citations supporting this statement were erroneously included despite the references not being present in the bibliography. This erratum corrects that citation error to maintain scientific accuracy.

Data Highlights

No numerical data is presented in this erratum; it solely addresses citation corrections.

Key Findings

• The original article contained incorrect in-text citations (references 46-51) in the discussion section.
• These references were not included in the reference list and thus were improperly cited.
• The sentence discussing the lack of an established pathophysiologic pathway linking romosozumab to cardiovascular effects has been corrected by removing these citations.
• The corrected sentence now stands without any reference citation, reflecting the current understanding accurately.
• The online version of the article has been updated to reflect this correction.

Clinical Implications

Clinicians should note that current evidence does not establish a mechanistic link between romosozumab and cardiovascular risk, and the corrected article reflects this accurately without unsupported citations. This correction ensures that clinical decisions are based on validated and properly referenced data.

Conclusion

This erratum clarifies and corrects citation errors in the original cardiovascular safety analysis of romosozumab, reinforcing the importance of accurate referencing in clinical research publications.

References

1. Stokar J and Szalat A 2024 -- Comparative Cardiovascular Safety of Romosozumab and PTH Analogues in Osteoporosis Management: A Propensity-Score-Matched Analysis (Erratum)